## Information for Patients:

### Neurologic Adverse Reactions

The following may be symptoms of ICANS:

- Confusion
- Difficulty with memory
- Difficulty speaking or slowed speech
- Difficulty understanding speech
- Loss of balance or coordination
- Disorientation
- Being less alert (decreased consciousness) or excessive sleepiness
- Loss of consciousness
- Delirious
- Fits (seizures)

Also, shaking, weakness with loss of movement on one side of the body, tremor, slow movements, or stiffness, which may be symptoms of parkinsonism.

▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See www.mhra.gov.uk/yellowcard for how to report side effects or search for MHRA Yellow Card in the Google Play or Apple App Store. Side effects should also be reported to Bristol-Myers Squibb Medical Information on 0800 731 1736 or medical.information@bms.com

This material fulfils a condition of the idecabtagene vicleucel marketing authorisation and has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA).

Date of preparation: Apr 2026
Approved by MHRA: Apr 2026
2012-GB-2600001

Patient Card — ABECMA® ▼ (idecabtagene vicleucel) — UK v3.0

▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information.
**Have this card with you at all times. Show it to any doctor/healthcare provider who sees you, including in conditions of emergency.**

- Tell any healthcare provider who sees you that you are being treated with idecabtagene vicleucel.
- For at least 2 weeks after receiving idecabtagene vicleucel, you should plan to stay close (within 2 hours of travel) to the location where you received treatment. Your doctor may recommend you stay longer to make sure the care you get after your treatment meets your individual needs.
- Do not drive, use machines or take part in activities that need you to be alert for at least 4 weeks after treatment or until your doctor tells you that you have completely recovered. Idecabtagene vicleucel may make you feel sleepy, may cause confusion or fits (seizures). Based on your individual needs, your doctor may advise you to wait longer before driving.

Bristol Myers Squibb®

Date of preparation: Apr 2026
Approved by MHRA: Apr 2026
2012-GB-2600001

## I have been treated with idecabtagene vicleucel

### Important Contact Information

My Name (PRINT): _____

Name of idecabtagene vicleucel Treating Physician (PRINT): _____

Office/Hospital Phone Number: _____

After-hours Phone Number: _____

Hospital Name: _____

Date of idecabtagene vicleucel Infusion (DD/MM/YYYY): _____

Lot Number (PRINT): _____

## Information for the Healthcare Provider:

This patient has received idecabtagene vicleucel CAR T cell therapy, a B-cell maturation antigen (BCMA) directed genetically modified autologous T cell immunotherapy.

**Following treatment with idecabtagene vicleucel, cytokine release syndrome (CRS) and/or neurologic toxicities, including immune effector cell-associated neurotoxicity syndrome (ICANS), may occur, which may be fatal or life threatening. CRS may involve any organ system.**

**Contact patient's idecabtagene vicleucel treating physician immediately for further information.**

Please see idecabtagene vicleucel's Summary of Product Characteristics and Package Leaflet, which can be found at www.medicines.org.uk/emc.

## Information for Patients:

Idecabtagene vicleucel may cause side effects that are severe or life-threatening. **Call your idecabtagene vicleucel treating physician or go to the accident & emergency department immediately if any of the following signs or symptoms appear:**

### Cytokine Release Syndrome (CRS)

- Fever
- Chills
- Difficulty breathing
- Low blood pressure
- Dizziness or light-headedness
- Nausea
- Headache
- Fast heartbeat
- Fatigue